Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | ATIC | P31939 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12421998 | 0.94 | MAPT (0.62) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL1993136 | 0.91 | MAPT (0.58) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL12421990 | 0.89 | MAPT (0.62) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL13391952 | 0.86 | MAPT (0.61) | MAPTSMN1; SMN2TP53POLBRXFP1 | |
| SCHEMBL24711222 | 0.82 | MAPT (0.67) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL2195695 | 0.80 | RAB9A (0.55) | MAPTSMN1; SMN2TP53HSD17B10POLB | |
| SCHEMBL12422198 | 0.79 | MAPT (0.56) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL2194080 | 0.79 | MAPT (0.54) | MAPTSMN1; SMN2TP53POLBRXFP1 | |
| SCHEMBL12422018 | 0.77 | TP53 (0.65) | MAPTSMN1; SMN2TP53ALDH1A1HPGD | |
| SCHEMBL12422003 | 0.76 | TP53 (0.64) | MAPTSMN1; SMN2TP53ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | MAPT 1/4885SMN1; SMN2 1022/4885TP53 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.